Medicine & Life Sciences
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
100%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
72%
Protein-Tyrosine Kinases
62%
Imatinib Mesylate
33%
Cytogenetics
19%
Leukemia
16%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14%
Leukemia, Myeloid, Chronic Phase
13%
Gastrointestinal Stromal Tumors
11%
Therapeutics
11%
Hematology
10%
United States Food and Drug Administration
9%
Clinical Trials
9%
Cytochrome P-450 CYP2C8
7%
Survival Rate
7%
Pharmacokinetics
7%
Cytochrome P-450 CYP3A Inhibitors
7%
Hypophosphatemia
6%
Pharmacology
6%
Cytochrome P-450 CYP2C9
6%
Philadelphia Chromosome
6%
Cytochrome P-450 CYP2D6
6%
Databases
5%
Medical Oncology
5%
Hydroxylation
5%
Cytochrome P-450 CYP3A
5%
Mutation
5%
Lipase
5%
Sudden Death
5%
Pruritus
5%
Constipation
5%
Metabolic Networks and Pathways
4%
Neutropenia
4%
Exanthema
4%
Drug Interactions
4%
Thrombocytopenia
4%
Hyperglycemia
4%
Nausea
4%
MEDLINE
4%
Vomiting
4%
Headache
4%
Fatigue
4%
Diarrhea
4%
Disease Progression
3%
Stomach
3%
Clinical Studies
3%
Serum
2%
Neoplasms
1%